Commonwealth Equity Services LLC Trims Stock Holdings in Pfizer Inc. (NYSE:PFE)

Commonwealth Equity Services LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 7.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,289,595 shares of the biopharmaceutical company’s stock after selling 333,757 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Pfizer were worth $123,497,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Briaud Financial Planning Inc acquired a new stake in shares of Pfizer during the 3rd quarter worth approximately $30,000. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer in the 3rd quarter valued at approximately $34,000. VisionPoint Advisory Group LLC increased its position in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the period. GoalVest Advisory LLC increased its position in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the period. Finally, Tennessee Valley Asset Management Partners acquired a new stake in Pfizer in the 4th quarter valued at approximately $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Finally, Morgan Stanley increased their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $36.00.

Pfizer Stock Up 2.4 %

PFE stock traded up $0.65 during trading hours on Thursday, reaching $27.83. 38,160,158 shares of the stock were exchanged, compared to its average volume of 42,557,941. The firm’s 50-day moving average is $26.87 and its 200-day moving average is $28.25. The company has a market cap of $157.59 billion, a price-to-earnings ratio of 77.25, a PEG ratio of 1.15 and a beta of 0.63. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.23 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.04%. Pfizer’s dividend payout ratio is 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.